度普利尤单抗联合外用他克莫司治疗特应性皮炎的疗效分析  

Analysis of therapeutic effect of Duprizumab combined with topical tacrolimus in treatment of atopic dermatitis

作　　者：李浩 刘高岗 录利锋 王豫平[2] LI Hao;LIU Gao-gang;LU Li-feng;WANG Yu-ping(Department of Dermatology,Henan Jingcheng Hospital of Traditional Chinese Dermatology,Zhengzhou 450000,China;Department of Dermatology and Venereology,Henan Provincial People's Hospital,Zhengzhou 450000,China)

机构地区：[1]河南京城皮肤中医院皮肤科,郑州450000 [2]河南省人民医院皮肤性病科,郑州450000

出　　处：《医药论坛杂志》2023年第9期89-92,共4页Journal of Medical Forum

摘　　要：目的 分析度普利尤单抗联合外用他克莫司治疗特应性皮炎的疗效。方法 做对比研究,回顾时间为2019年1月至2021年12月,共得特应性皮炎患者94例,以治疗方式为分组标准,得到对照组(n=47、度普利尤单抗治疗治疗)与观察组(n=47、度普利尤单抗联合外用他克莫司治疗),分析相关病理指标变化,观其症状改善情况,比较生活质量与负性情绪,统计不良反应并综合分析其疗效。结果 治疗后,观察组血清总IgE、外周血Egb水平低于对照组(P<0.05),观察组EASI、NRS、Scoread评分低于对照组(P<0.05),观察组DLQI、SAS、SDS低于对照组(P<0.05);在不良反应方面,两组无显著差异(P>0.05);在疗效方面,观察组比对照组高(P<0.05)。结论 度普利尤单抗联合外用他克莫司治疗特应性皮炎的疗效较显著,可提高其免疫力,还可快速改善临床症状、生活质量及负性情绪,值得推广。Objective To analyze the efficacy of Duprizumab combined with topical tacrolimus in the treatment of atopic dermatitis.Methods A comparative study was conducted,with a retrospective period of January 2019 to December 2021.A total of 94 patients with atopic dermatitis were identified,and treatment methods were used as grouping criteria.A control group(n=47,treated with Dupriumab)and an observation group(n=47,treated with Dupriumab in combi⁃nation with topical tacrolimus)were obtained.The changes in relevant pathological indicators were analyzed,the im⁃provement of symptoms was observed,and the quality of life and negative emotions were compared,adverse reactions were collected and their therapeutic effects were comprehensively analyzed.Results After treatment,the total serum IgE and peripheral blood Egb levels in the observation group were lower than those of the control group(P<0.05).The EASI,NRS,and Scoread scores in the observation group were lower than those of the control group(P<0.05).The DLQI,SAS,and SDS scores in the observation group were lower than those of the control group(P<0.05);In terms of adverse reactions,there was no significant difference between the two groups(P>0.05);In terms of efficacy,the ob⁃servation group was higher than that of the control group(P<0.05).Conclusion The combination of Duprizumab and topical tacrolimus has a significant therapeutic effect on atopic dermatitis,which can enhance its immunity and quickly improve clinical symptoms,quality of life,and negative emotions.It is worth promoting.

关 键 词：度普利尤单抗 特应性皮炎 临床疗效 生活质量 

分 类 号：R758.2[医药卫生—皮肤病学与性病学]